Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Parallel-controlled, Multi-center Phase III Study (NEOTORCH-BREAST04)

NCT06977893 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

194

Enrollment

OTHER

Sponsor class

Conditions

HR+/HER2- Breast Cancer

Interventions

DRUG: Neoadjuvant Chemotherapy in Combination with Toripalimab
DRUG: Neoadjuvant Chemotherapy

Sponsor

First Affiliated Hospital of Zhejiang University